Compare BioNano Genomics Inc (BNGO) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs VNET Group Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while VNET Group Inc trades at $7.46 (market cap $2.14B). The key difference: VNET Group Inc is far larger — about 156.7× BioNano Genomics Inc's market cap, and VNET Group Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | VNET | |
|---|---|---|
Market Cap | $13.66M | $2.14B |
Sector | Health | Technology |
52-Week High | $4.92 | $14.03 |
52-Week Low | $1.06 | $6.29 |
Enterprise Value | $16.26M | $5.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
VNET trades at $7.565, up 1.14% today, with a neutral technical signal. The stock shows mixed fundamentals: revenue grew to $9.95B in 2025, but net losses deepened to -$256.77M. Recent news highlights strategic investor entry and AI-driven data center demand, yet earnings misses and a class action settlement pose concerns. Cash flow remains positive from financing, but profitability metrics like ROE at -43.21% signal challenges.
Outlook is cautious; analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt-to-asset ratio of 50.18% heighten risk. Investors should weigh growth potential from AI expansion against execution and competitive pressures in China's data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
